{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:10Z","timestamp":1786118950556,"version":"build-2736575974"},"reference-count":114,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1080\/10673220802075852","type":"journal-article","created":{"date-parts":[[2008,4,15]],"date-time":"2008-04-15T23:16:55Z","timestamp":1208301415000},"page":"97-112","source":"Crossref","is-referenced-by-count":59,"title":["Pharmacological Treatment Options for Autism Spectrum Disorders in Children and Adolescents"],"prefix":"10.1097","volume":"16","author":[{"given":"Thomas J.","family":"Leskovec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brieana M.","family":"Rowles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Findling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"issue":"suppl 10","key":"R2-4-20210129","first-page":"38","article-title":"Treatment planning for patients with autism spectrum disorders.","volume":"66","author":"Aman","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"R4-4-20210129","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1517\/14656566.2.4.587","article-title":"Pharmacotherapeutic management of autism.","volume":"2","author":"Posey","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"R5-4-20210129","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1023\/A:1005559725475","article-title":"Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders.","volume":"30","author":"Aman","year":"2000","journal-title":"J Autism Dev Disord"},{"key":"R6-4-20210129","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.chc.2005.08.005","article-title":"An update on pharmacologic treatments for autism spectrum disorders.","volume":"15","author":"King","year":"2006","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"R7-4-20210129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1089\/cap.2005.15.116","article-title":"Medication patterns in patients with autism: temporal, regional, and demographic influences.","volume":"15","author":"Aman","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R8-4-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/1044546041649011","article-title":"Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: an open-pilot study.","volume":"14","author":"DiMartino","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R9-4-20210129","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1023\/A:1005548619694","article-title":"Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder.","volume":"30","author":"Handen","year":"2000","journal-title":"J Autism Dev Disord"},{"key":"R10-4-20210129","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/archpsyc.62.11.1266","article-title":"Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity.","volume":"62","year":"2005","journal-title":"Arch Gen Psychiatry"},{"issue":"suppl 2","key":"R11-4-20210129","doi-asserted-by":"crossref","first-page":"26S","DOI":"10.1097\/00004583-200202001-00003","article-title":"Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.","volume":"41","author":"Greenhill","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R12-4-20210129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1017\/S0033291700002014","article-title":"Phenomenology and classification of the childhood psychoses.","volume":"18","author":"Volkmar","year":"1988","journal-title":"Psychol Med"},{"key":"R13-4-20210129","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF01538168","article-title":"Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children.","volume":"2","author":"Campbell","year":"1972","journal-title":"J Autism Child Schizophr"},{"key":"R14-4-20210129","first-page":"70","article-title":"Levodopa and levoamphetamine: a crossover study in young schizophrenic children.","volume":"19","author":"Campbell","year":"1976","journal-title":"Curr Ther Res Clin Exp"},{"key":"R15-4-20210129","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1097\/01.chi.0000231976.28719.2a","article-title":"Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial.","volume":"45","author":"Arnold","year":"2006","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"RU16-4-20210129","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1089\/cap.2005.15.325","article-title":"Retrospective assessment of atomoxetine in children and adolescents with pervasive developmental disorders.","volume":"15","author":"Jou","year":"2005","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"RU17-4-20210129","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2006.16.611","article-title":"Atomoxetine for attention-deficithyperactivity disorder symptoms in children with pervasive developmental disorders: a pilot study.","volume":"16","author":"Troost","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"RU18-4-20210129","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1089\/cap.2006.16.599","article-title":"Open-label atomoxetine for attention-deficit hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.","volume":"16","author":"Posey","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R19-4-20210129","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0033-3182(65)72256-1","article-title":"Amitriptyline in treatment of hyperkinetic children. A double-blind study.","volume":"6","author":"Krakowski","year":"1965","journal-title":"Psychosomatics"},{"key":"R20-4-20210129","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/clpt.1986.13","article-title":"Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response.","volume":"39","author":"Donnelly","year":"1986","journal-title":"Clin Pharmacol Ther"},{"key":"R21-4-20210129","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/00004583-198909000-00022","article-title":"A double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy.","volume":"28","author":"Biederman","year":"1989","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R22-4-20210129","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1176\/ajp.149.3.363","article-title":"Differential response of seven subjects with autistic disorder to clomipramine and desipramine.","volume":"149","author":"Gordon","year":"1992","journal-title":"Am J Psychiatry"},{"key":"R23-4-20210129","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/archpsyc.1993.01820180039004","article-title":"A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder.","volume":"50","author":"Gordon","year":"1993","journal-title":"Arch Gen Psychiatry"},{"key":"R24-4-20210129","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2466\/pms.1988.66.3.763","article-title":"Motor performance in hyperactive children treated with imipramine.","volume":"66","author":"Gualtieri","year":"1988","journal-title":"Percept Mot Skills"},{"key":"R25-4-20210129","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/BF01557348","article-title":"Imipramine in preschool autistic and schizophrenic children.","volume":"1","author":"Campbell","year":"1971","journal-title":"J Autism Child Schizophr"},{"key":"R26-4-20210129","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1089\/10445460050167304","article-title":"A controlled study of nortriptyline in children and adolescents with attention deficit hyperactivity disorder.","volume":"10","author":"Prince","year":"2000","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R27-4-20210129","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00004583-199303000-00015","article-title":"Nortriptyline in the treatment of ADHD: a chart review of 58 cases.","volume":"32","author":"Wilens","year":"1993","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R28-4-20210129","first-page":"298","article-title":"Clinical study of the response to nortriptyline on autistic children.","volume":"2","author":"Kurtis","year":"1966","journal-title":"Int J Neuropsychiatry"},{"key":"R29-4-20210129","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.pnpbp.2005.10.002","article-title":"Low-dose venlafaxine in three adolescents and young adults with autistic disorder improves self-injurious behavior and attention deficithyperactivity disorders (ADHD)-like symptoms.","volume":"30","author":"Carminati","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R30-4-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/088307380001500214","article-title":"Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report.","volume":"15","author":"Hollander","year":"2000","journal-title":"J Child Neurol"},{"key":"RU31-4-20210129","first-page":"184","article-title":"Venlafaxine in adults with attention-deficithyperactivity disorder: an open clinical trial.","volume":"57","author":"Findling","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"RU32-4-20210129","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/cap.1996.6.241","article-title":"An open trial of venlafaxine in the treatment of attention-deficithyperactivity disorder in children and adolescents.","volume":"6","author":"Olvera","year":"1996","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"RU33-4-20210129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/cap.2007.0119","article-title":"Venlafaxine in the treatment of children and adolescents with attention-deficithyperactivity disorder.","volume":"17","author":"Findling","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"RU34-4-20210129","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/00004583-199610000-00018","article-title":"Bupropion hydrochloride in attention deficit disorder with hyperactivity.","volume":"35","author":"Conners","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"RU35-4-20210129","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1177\/070674378603100617","article-title":"Bupropion effects in attention deficit and conduct disorders.","volume":"31","author":"Simeon","year":"1986","journal-title":"Can J Psychiatry"},{"key":"RU36-4-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0006-3223(02)01664-5","article-title":"An open trial of bupropion for the treatment of adults with attention-deficithyperactivity disorder and bipolar disorder.","volume":"54","author":"Wilens","year":"2003","journal-title":"Biol Psychiatry"},{"key":"R37-4-20210129","first-page":"77","article-title":"A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism.","volume":"53","author":"Fankhauser","year":"1992","journal-title":"J Clin Psychiatry"},{"key":"R38-4-20210129","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/00004714-199210000-00005","article-title":"Clonidine treatment of hyperactive and impulsive children with autistic disorder.","volume":"12","author":"Jaselskis","year":"1992","journal-title":"J Clin Psychopharmacol"},{"key":"R39-4-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/1044546041649084","article-title":"Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: a retrospective analysis of 80 cases.","volume":"14","author":"Posey","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R40-4-20210129","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1089\/cap.2006.16.589","article-title":"A prospective open trial of guanfacine in children with pervasive developmental disorders.","volume":"16","author":"Scahill","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R41-4-20210129","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/1087054705284091","article-title":"Donepezil in the treatment of ADHD-like symptoms in youths with pervasive developmental disorder: a case series.","volume":"9","author":"Doyle","year":"2006","journal-title":"J Atten Disord"},{"key":"R42-4-20210129","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1089\/cap.2006.16.621","article-title":"A prospective, open-label trial of galantamine in autistic disorder.","volume":"16","author":"Nicolson","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R43-4-20210129","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1089\/cap.2006.16.517","article-title":"A prospective, open-label trial of memantine in the treatment of cognitive, behavioral, and memory dysfunction in pervasive developmental disorders.","volume":"16","author":"Owley","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R44-4-20210129","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1176\/appi.ajp.162.7.1361","article-title":"Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months.","volume":"162","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R45-4-20210129","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/BF01531306","article-title":"The effects of haloperidol on learning and behavior in autistic children.","volume":"12","author":"Campbell","year":"1982","journal-title":"J Autism Dev Disord"},{"key":"R46-4-20210129","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1176\/ajp.145.3.335","article-title":"Low-dose neuroleptic therapy for children with childhood-onset pervasive developmental disorder.","volume":"145","author":"Joshi","year":"1988","journal-title":"Am J Psychiatry"},{"key":"R47-4-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02211843","article-title":"The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children.","volume":"19","author":"Anderson","year":"1989","journal-title":"J Autism Dev Disord"},{"key":"R48-4-20210129","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/ajp.141.10.1195","article-title":"Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms.","volume":"141","author":"Anderson","year":"1984","journal-title":"Am J Psychiatry"},{"key":"R49-4-20210129","first-page":"187","article-title":"Pimozide in autistic children.","volume":"28","author":"Ernst","year":"1992","journal-title":"Psychopharmacol Bull"},{"key":"R50-4-20210129","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/00004583-199706000-00022","article-title":"Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study.","volume":"36","author":"Campbell","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R51-4-20210129","doi-asserted-by":"crossref","first-page":"479","DOI":"10.4088\/JCP.v62n0612h","article-title":"Clozapine in the treatment of aggression in an adolescent with autistic disorder.","volume":"62","author":"Chen","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R52-4-20210129","first-page":"340","article-title":"Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behaviour.","volume":"26","author":"Gobbi","year":"2001","journal-title":"J Psychiatry Neurosci"},{"key":"R53-4-20210129","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/ajp.153.5.738a","article-title":"Clinical effects of clozapine on autistic disorder.","volume":"153","author":"Zuddas","year":"1996","journal-title":"Am J Psychiatry"},{"key":"R54-4-20210129","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1474-4422(02)00160-6","article-title":"Epilepsy in autism.","volume":"1","author":"Tuchman","year":"2002","journal-title":"Lancet Neurol"},{"key":"R55-4-20210129","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJMoa013171","article-title":"Risperidone in children with autism and serious behavioral problems.","volume":"347","author":"McCracken","year":"2002","journal-title":"N Engl J Med"},{"key":"R56-4-20210129","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1176\/appi.ajp.162.6.1142","article-title":"Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology.","volume":"162","author":"McDougle","year":"2005","journal-title":"Am J Psychiatry"},{"key":"R57-4-20210129","doi-asserted-by":"crossref","first-page":"e634","DOI":"10.1542\/peds.2003-0264-F","article-title":"Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.","volume":"114","author":"Shea","year":"2004","journal-title":"Pediatrics"},{"key":"R58-4-20210129","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1097\/01.chi.0000177055.11229.76","article-title":"Long-term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study.","volume":"44","author":"Troost","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R59-4-20210129","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1089\/cap.2006.16.575","article-title":"Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy.","volume":"16","author":"Luby","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R60-4-20210129","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.55.7.633","article-title":"A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.","volume":"55","author":"McDougle","year":"1998","journal-title":"Arch Gen Psychiatry"},{"key":"R61-4-20210129","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1089\/cap.2006.16.541","article-title":"A double-blind placebo-controlled pilot study of olanzapine in childhoodadolescent pervasive developmental disorder.","volume":"16","author":"Hollander","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"RU62-4-20210129","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/00004714-200210000-00003","article-title":"Open-label study of olanzapine in children with pervasive developmental disorder.","volume":"22","author":"Kemner","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"RU63-4-20210129","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/00004583-199809000-00006","article-title":"Olanzapine for autistic disorder with hyperactivity.","volume":"37","author":"Malek-Ahmadi","year":"1998","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"RU64-4-20210129","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1097\/00004583-200108000-00009","article-title":"Olanzapine versus haloperidol in children with autistic disorder: an open pilot study.","volume":"40","author":"Malone","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"RU65-4-20210129","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004714-199902000-00008","article-title":"Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study.","volume":"19","author":"Potenza","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R66-4-20210129","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1089\/1044546041649129","article-title":"Quetiapine in nine youths with autistic disorder.","volume":"14","author":"Findling","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R67-4-20210129","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/cap.1999.9.99","article-title":"Open-label quetiapine in the treatment of children and adolescents with autistic disorder.","volume":"9","author":"Martin","year":"1999","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R68-4-20210129","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.4088\/JCP.v65n1115","article-title":"A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders.","volume":"65","author":"Corson","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R69-4-20210129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s10803-005-3306-1","article-title":"Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders.","volume":"35","author":"Hardan","year":"2005","journal-title":"J Autism Dev Disord"},{"key":"R70-4-20210129","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4088\/JCP.v65n0119","article-title":"The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment.","volume":"65","author":"Cohen","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"RU71-4-20210129","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1440-1614.2003.01279.x","article-title":"Improvement in behaviour and attention in an autistic patient treated with ziprasidone.","volume":"37","author":"Goforth","year":"2003","journal-title":"Aust N Z J Psychiatry"},{"key":"R72-4-20210129","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00004583-200208000-00010","article-title":"Case series: use of ziprasidone for maladaptive symptoms in youths with autism.","volume":"41","author":"McDougle","year":"2002","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R73-4-20210129","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/cap.2004.14.455","article-title":"Aripiprazole for maladaptive behavior in pervasive developmental disorders.","volume":"14","author":"Stigler","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R74-4-20210129","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/cap.2006.16.549","article-title":"Clinical effects and adverse reactions of off-label use of ariprazole in children and adolescents with developmental disabilities.","volume":"16","author":"Valicenti-McDermott","year":"2006","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R75-4-20210129","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1089\/cap.2004.14.426","article-title":"A retrospective assessment of topiramate in children and adolescents with pervasive developmental disorders.","volume":"14","author":"Hardan","year":"2004","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R76-4-20210129","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1017\/S1461145705005791","article-title":"Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder.","volume":"9","author":"Hollander","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"key":"R77-4-20210129","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/BF01487073","article-title":"Open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults.","volume":"17","author":"Ratey","year":"1987","journal-title":"J Autism Dev Disord"},{"key":"R78-4-20210129","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/archfami.6.4.368","article-title":"Treatment with buspirone in a patient with autism.","volume":"6","author":"McCormick","year":"1997","journal-title":"Arch Fam Med"},{"key":"R79-4-20210129","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/00004714-198904000-00009","article-title":"Clinical effect of buspirone in autistic children.","volume":"9","author":"Realmuto","year":"1989","journal-title":"J Clin Psychopharmacol"},{"key":"R80-4-20210129","doi-asserted-by":"crossref","first-page":"56","DOI":"10.4088\/JCP.v59n0203","article-title":"Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study.","volume":"59","author":"Buitelaar","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"R81-4-20210129","doi-asserted-by":"crossref","first-page":"923","DOI":"10.2165\/00023210-200519110-00003","article-title":"Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders.","volume":"19","author":"Malone","year":"2005","journal-title":"CNS Drugs"},{"key":"R82-4-20210129","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00004583-200107000-00011","article-title":"Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.","volume":"40","author":"Geller","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R83-4-20210129","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/00004583-199211000-00011","article-title":"Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder.","volume":"31","author":"Riddle","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R84-4-20210129","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/00004583-199207000-00024","article-title":"Fluoxetine treatment of children and adults with autistic disorder and mental retardation.","volume":"31","author":"Cook","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R85-4-20210129","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1469-8749.1998.tb15414.x","article-title":"Effects of fluoxetine treatment in young children with idiopathic autism.","volume":"40","author":"DeLong","year":"1998","journal-title":"Dev Med Child Neurol"},{"key":"R86-4-20210129","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1023\/A:1026008602540","article-title":"Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial.","volume":"28","author":"Fatemi","year":"1998","journal-title":"J Autism Dev Disord"},{"key":"R87-4-20210129","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.npp.1300627","article-title":"A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism.","volume":"30","author":"Hollander","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"R88-4-20210129","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1023\/A:1022234605695","article-title":"Low-dose fluvoxamine treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study.","volume":"33","author":"Martin","year":"2003","journal-title":"J Autism Dev Disord"},{"key":"R89-4-20210129","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1023\/A:1005551523657","article-title":"Repetitive thoughts and behavior in pervasive developmental disorders: treatment with serotonin reuptake inhibitors.","volume":"30","author":"McDougle","year":"2000","journal-title":"J Autism Dev Disord"},{"key":"R90-4-20210129","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1097\/00004583-200110000-00011","article-title":"Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder.","volume":"40","author":"Cook","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R91-4-20210129","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/jama.280.20.1752","article-title":"Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.","volume":"280","author":"March","year":"1998","journal-title":"JAMA"},{"key":"R92-4-20210129","first-page":"333","article-title":"Sertraline response in adults with mental retardation and autistic disorder.","volume":"57","author":"Hellings","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"R93-4-20210129","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/00004714-199802000-00010","article-title":"Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation.","volume":"18","author":"McDougle","year":"1998","journal-title":"J Clin Psychopharmacol"},{"key":"R94-4-20210129","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/cap.1997.7.9","article-title":"Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder.","volume":"7","author":"Steingard","year":"1997","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"R95-4-20210129","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/01.chi.0000138356.29099.f1","article-title":"Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial.","volume":"43","author":"Geller","year":"2004","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R96-4-20210129","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/00004583-199902000-00004","article-title":"Paroxetine in autism.","volume":"38","author":"Posey","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R97-4-20210129","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/00004583-199407000-00022","article-title":"Paroxetine for self-injurious behavior.","volume":"33","author":"Snead","year":"1994","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R98-4-20210129","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1352\/0895-8017(1998)102<0427:PTOAAS>2.0.CO;2","article-title":"Paroxetine treatment of aggression and self-injury in persons with mental retardation.","volume":"102","author":"Davanzo","year":"1998","journal-title":"Am J Ment Retard"},{"key":"R99-4-20210129","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00004703-200304000-00005","article-title":"Use of citalopram in pervasive developmental disorders.","volume":"24","author":"Namerow","year":"2003","journal-title":"J Dev Behav Pediatr"},{"key":"R100-4-20210129","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/01.chi.0000153229.80215.a0","article-title":"An open-label trial of escitalopram in pervasive developmental disorders.","volume":"44","author":"Owley","year":"2005","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R101-4-20210129","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00004583-199201000-00008","article-title":"Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disordera multicenter trial.","volume":"31","author":"DeVeaugh-Geiss","year":"1992","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R102-4-20210129","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/00004714-200108000-00012","article-title":"Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study.","volume":"21","author":"Remington","year":"2001","journal-title":"J Clin Psychopharmacol"},{"key":"R103-4-20210129","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/00004583-199604000-00021","article-title":"A pilot study of clomipramine in young autistic children.","volume":"35","author":"Sanchez","year":"1996","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R104-4-20210129","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","article-title":"A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.","volume":"56","author":"Goff","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"R105-4-20210129","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1176\/appi.ajp.161.11.2115","article-title":"A pilot study of D-cycloserine in subjects with autistic disorder.","volume":"161","author":"Posey","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R106-4-20210129","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.jcp.0000177667.35016.e9","article-title":"Tetrahydrobiopterin in the treatment of children with autistic disorder: a double-blind placebo-controlled crossover study.","volume":"25","author":"Danfors","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"R107-4-20210129","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/00004714-198712000-00005","article-title":"Lithium carbonate in the treatment of two patients with infantile autism and atypical bipolar symptomatology.","volume":"7","author":"Kerbeshian","year":"1987","journal-title":"J Clin Psychopharmacol"},{"key":"R108-4-20210129","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/mrdd.20062","article-title":"Novel treatments for autistic spectrum disorders.","volume":"11","author":"Levy","year":"2005","journal-title":"Ment Retard Dev Disabil Res Rev"},{"key":"RU109-4-20210129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00004583-199502000-00018","article-title":"Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.","volume":"34","author":"Kolmen","year":"1995","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"RU110-4-20210129","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/0006-3223(95)00297-9","article-title":"The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.","volume":"39","author":"Willemsen-Swinkels","year":"1996","journal-title":"Biol Psychiatry"},{"key":"RU111-4-20210129","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0165-1781(95)02749-M","article-title":"Placebo-controlled acute dosage naltrexone study in young autistic children.","volume":"58","author":"Willemsen-Swinkels","year":"1995","journal-title":"Psychiatry Res"},{"key":"R112-4-20210129","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00004583-199905000-00021","article-title":"Naltrexone and communication skills in young children with autism.","volume":"38","author":"Feldman","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R113-4-20210129","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJM199912093412404","article-title":"Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder.","volume":"341","author":"Sandler","year":"1999","journal-title":"N Engl J Med"},{"key":"R114-4-20210129","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/1362361305053257","article-title":"Randomized controlled trial of transdermal secretin on behavior of children with autism.","volume":"9","author":"Ratliff-Schaub","year":"2005","journal-title":"Autism"},{"key":"R115-4-20210129","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1023\/A:1025861522935","article-title":"High-dose pyridoxine and magnesium administration in children with autistic disorder: an absence of salutary effects in a double-blind, placebo-controlled study.","volume":"27","author":"Findling","year":"1997","journal-title":"J Autism Dev Disord"},{"key":"R116-4-20210129","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1023\/A:1023023820671","article-title":"A double-blind, placebo-controlled, crossover pilot trial of low dose dimethylglycine in patients with autistic disorder.","volume":"29","author":"Bolman","year":"1999","journal-title":"J Autism Dev Disord"}],"container-title":["Harvard Review of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00023727-200803000-00004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:01:00Z","timestamp":1786035660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00023727-200803000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1080\/10673220802075852","relation":{},"ISSN":["1067-3229"],"issn-type":[{"value":"1067-3229","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}